{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:51:13Z","timestamp":1788375073453,"version":"build-2803163510"},"reference-count":147,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Infections by Gram-negative multi-drug resistant (MDR) bacterial species are difficult to treat using available antibiotics. Overuse of carbapenems has contributed to widespread resistance to these antibiotics; as a result, carbapenem-resistant Enterobacterales (CRE), <jats:italic>A. baumannii<\/jats:italic> (CRAB), and <jats:italic>P. aeruginosa<\/jats:italic> (CRPA) have become common causes of healthcare-associated infections. Carbapenems, tigecycline, and colistin are the last resource antibiotics currently used; however, multiple reports of resistance to these antimicrobial agents have been documented worldwide. Recently, new antibiotics have been evaluated against Gram-negatives, including plazomicin (a new aminoglycoside) to treat CRE infection, eravacycline (a novel tetracycline) with <jats:italic>in vitro<\/jats:italic> activity against CRAB, and cefiderocol (a synthetic conjugate) for the treatment of nosocomial pneumonia by carbapenem-non-susceptible Gram-negative isolates. Furthermore, combinations of known \u03b2-lactams with recently developed \u03b2-lactam inhibitors, such as ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime-tazobactam, and meropenem-vaborbactam, has been suggested for the treatment of infections by extended-spectrum \u03b2-lactamases, carbapenemases, and AmpC producer bacteria. Nonetheless, they are not active against all carbapenemases, and there are reports of resistance to these combinations in clinical isolates.This review summarizes and discusses the <jats:italic>in vitro<\/jats:italic> and clinical evidence of the recently approved antibiotics, \u03b2-lactam inhibitors, and those in advanced phases of development for treating MDR infections caused by Gram-negative multi-drug resistant (MDR) bacterial species.<\/jats:p>","DOI":"10.3389\/fcimb.2022.884365","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T10:07:41Z","timestamp":1662545261000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens"],"prefix":"10.3389","volume":"12","author":[{"given":"Flora","family":"Cruz-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Mart\u00ednez-Mel\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayo","family":"Morfin-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Rodriguez-Noriega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor J.","family":"Maldonado-Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Garza-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3201\/eid\/1706.091866","article-title":"Multidrug-Resistant Acinetobacter Baumannii Harboring OXA-24 Carbapenemase, Spain","volume":"17","author":"Acosta","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1590\/S1980-220X2018001903474","article-title":"Epidemiological Profile of Healthcare-Associated Infections Caused by Carbapenemase-Producing Enterobacteriaceae","volume":"53","author":"Alvim","year":"2019","journal-title":"Rev. Esc. Enferm. USP."},{"key":"B3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1098\/rstb.1980.0049","article-title":"The Structure of Beta-Lactamases","volume":"289","author":"Ambler","year":"1980","journal-title":"Philos. Trans. R. Soc. Lond. B. Biol. Sci."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02584-20","article-title":"Epidemiology and Transmission of Carbapenemase-Producing Enterobacteriaceae in a Health Care Network of an Acute-Care Hospital and Its Affiliated Intermediate- and Long-Term-Care Facilities in Singapore","volume":"65","author":"Aung","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.ijantimicag.2018.07.011","article-title":"Assessing the In Vitro Activity of Ceftazidime\/Avibactam and Aztreonam Among Carbapenemase-Producing Enterobacteriaceae: Defining the Zone of Hope","volume":"52","author":"Avery","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12941-016-0136-2","article-title":"Phenotypic and Genotypic Characteristics of Carbapenem-Resistant Enterobacteriaceae in a Tertiary-Level Reference Hospital in Turkey","volume":"15","author":"Baran","year":"2016","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e00159","DOI":"10.1128\/mBio.00159-19","article-title":"Targeting Multidrug-Resistant","volume":"10","author":"Barnes","year":"2019","journal-title":"mBio"},{"key":"B8","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and Safety of Cefiderocol or Best Available Therapy for the Treatment of Serious Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria (CREDIBLE-CR): A Randomised, Open-Label, Multicentre, Pathogen-Focused, Descriptive, Phase 3 Trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/2049936120912049","article-title":"How to Manage KPC Infections","volume":"7","author":"Bassetti","year":"2020","journal-title":"Ther. Adv. Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/841951","article-title":"Carbapenemases in Gram-Negative Bacteria: Laboratory Detection and Clinical Significance","volume":"2014","author":"Bedeni\u0107","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e00397","DOI":"10.1128\/AAC.00397-20","article-title":"Metallo-\u03b2-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline","volume":"64","author":"Boyd","year":"2020","journal-title":"Antimicrob. Agents Chemother"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1021\/acsinfecdis.9b00217","article-title":"Design of Next Generation Polymyxins With Lower Toxicity: The Discovery of SPR206","volume":"5","author":"Brown","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00739-21","article-title":"Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Polymyxin Derivative Spr206","volume":"65","author":"Bruss","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"a025247","DOI":"10.1101\/cshperspect.a025247","article-title":"\u03b2-Lactams and \u03b2-Lactamase Inhibitors: An Overview","volume":"6","author":"Bush","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1128\/aac.01009-09","article-title":"Updated Functional Classification of Beta-Lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"ofx176","DOI":"10.1093\/ofid\/ofx176","article-title":"Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter Baumannii and Pseudomonas Aeruginosa","volume":"4","author":"Cai","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/ofid\/ofy347","article-title":"Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among","volume":"6","author":"Castanheira","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1469-0691.2004.00872.x","article-title":"Antimicrobial Susceptibility of Streptococcus Pneumoniae in Latin America: Results From Five Years of the SENTRY Antimicrobial Surveillance Program","volume":"10","author":"Castanheira","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"B19","doi-asserted-by":"publisher","first-page":"S313","DOI":"10.1093\/ofid\/ofz360.758","article-title":"690. Activity of a Novel Polymyxin Analog, QPX9003, Tested Against Resistant Gram-Negative Pathogens, Including Carbapenem-Resistant Acinetobacter, Enterobacterales, and Pseudomonas","volume":"6","author":"Castanheira","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"S313","DOI":"10.1556\/030.2021.01626","article-title":"Ceftazidime\/avibactam Resistance Is Associated With Different Mechanisms in KPC-Producing Klebsiella Pneumoniae Strains","volume":"6","author":"Cavallini","year":"2021","journal-title":"Acta. Microbiol. Immunol. Hung."},{"key":"B21","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ajic.2018.10.025","article-title":"The Impact of Carbapenem-Resistant Pseudomonas Aeruginosa on Clinical and Economic Outcomes in a Chinese Tertiary Care Hospital: A Propensity Score-Matched Analysis","volume":"47","author":"Chen","year":"2019","journal-title":"Am. J. Infect. Control"},{"key":"B22","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/jac\/dkz497","article-title":"Pharmacokinetics and Safety of Aztreonam\/Avibactam for the Treatment of Complicated Intra-Abdominal Infections in Hospitalized Adults: Results From the REJUVENATE Study","volume":"75","author":"Cornely","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1093\/jac\/dkaa095","article-title":"In Vitro Synergy of Ceftolozane\/Tazobactam in Combination With Fosfomycin or Aztreonam Against MDR Pseudomonas Aeruginosa","volume":"75","author":"Cuba","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ijantimicag.2018.11.015","article-title":"Clinical Characteristics and Prognosis of Infections Caused by OXA-48 Carbapenemase-Producing Enterobacteriaceae in Patients Treated With Ceftazidime-Avibactam","volume":"53","author":"De la Calle","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1007\/s10096-017-3063-z","article-title":"Activity of the Novel Siderophore Cephalosporin Cefiderocol Against Multidrug-Resistant Gram-Negative Pathogens","volume":"36","author":"Dobias","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1128\/AAC.44.1.196-199.2000","article-title":"Sequence Analysis of ARI-1, a Novel OXA Beta-Lactamase, Responsible for Imipenem Resistance in Acinetobacter Baumannii 6B92","volume":"44","author":"Donald","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"17104","DOI":"10.1038\/nmicrobiol.2017.104","article-title":"ETX2514 is a Broad-Spectrum \u03b2-Lactamase Inhibitor for the Treatment of Drug-Resistant Gram-Negative Bacteria Including Acinetobacter Baumannii","volume":"2","author":"Durand-R\u00e9ville","year":"2017","journal-title":"Nat. Microbiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e00892","DOI":"10.1128\/AAC.00892-19","article-title":"). Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator, After Single and Multiple Ascending Doses and When Combined With \u03b2-Lactam Antibiotics in Healthy Subjects","volume":"63","author":"Eckburg","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e00010","DOI":"10.1128\/AAC.00010-19","article-title":"Aztreonam Plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-\u03b2-Lactamase-Producing Gram-Negative Bacteria","volume":"63","author":"Emeraud","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of Ceftazidime-Avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-\u03b2-Lactamase-Producing Enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter Baumannii","volume":"21","author":"Falcone","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ijantimicag.2018.01.011","article-title":"Activity of Ceftazidime-Avibactam Against Carbapenemase-Producing Enterobacteriaceae From Urine Specimens Obtained During the Infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST) in Spain","volume":"51","author":"Garc\u00eda-Castillo","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1089\/mdr.2019.0354","article-title":"The Evolution of Antimicrobial Resistance in Mexico During the Last Decade: Results From the INVIFAR Group","volume":"26","author":"Garza-Gonz\u00e1lez","year":"2020","journal-title":"Microb. Drug Resist."},{"key":"B34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.eimce.2017.07.003","article-title":"Detection of Carbapenemases and Other Mechanisms of Enzymatic Resistance to Beta-Lactams in Enterobacteriaceae With Diminished Susceptibility to Carbapenems in a Tertiary Care Hospital","volume":"36","author":"G\u00f3mara-Lomero","year":"2018","journal-title":"Enferm. Infecc. Microbiol. Clin"},{"key":"B35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ijid.2019.06.017","article-title":"National Prevalence Estimates for Resistant Enterobacteriaceae and Acinetobacter Species in Hospitalized Patients in the United States","volume":"85","author":"Gupta","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10101179","article-title":"In Vivo Pharmacodynamics of Beta-Lactams\/Nacubactam Against Carbapenem-Resistant And\/or Carbapenemase-Producing Enterobacter Cloacae and Klebsiella Pneumoniae in Murine Pneumonia Model","volume":"10","author":"Hagihara","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"B37","first-page":"93","article-title":"Carbapenem-Resistant, Gram-Negative Bacilli: The State of the Art","volume-title":"Atibiotic Resistance, Mechanisms and New Antimicrobial Approaches","author":"Halat","year":"2016"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/jac\/dki130","article-title":"Revised Ambler Classification of {Beta}-Lactamases","volume":"55","author":"Hall","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01963-19","article-title":"VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-Beta-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas Aeruginosa","volume":"64","author":"Hamrick","year":"2020","journal-title":"Antimicrob. Agents. Chemother."},{"key":"B40","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E Coli or Klebsiella Pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"B41","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jama.2018.12565","article-title":"Carbapenem-Sparing Therapy for Extended-Spectrum \u03b2-Lactamase-Producing E Coli and Klebsiella Pneumoniae Bloodstream Infection: The Search Continues","volume":"320","author":"Hayden","year":"2018","journal-title":"JAMA"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a Cyclic Boronic Acid Beta-Lactamase Inhibitor (RPX7009) With Utility vs Class a Serine Carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"J. Med. Chem."},{"key":"B43","doi-asserted-by":"publisher","first-page":"aac0216121","DOI":"10.1128\/aac.02161-21","article-title":"In Vitro Activity of Cefepime-Taniborbactam Against Carbapenemase Producing Enterobacterales and Pseudomonas Aeruginosa Isolates Recovered in Spain","volume":"66","author":"Hern\u00e1ndez-Garc\u00eda","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B44","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/1120009X.2021.1940793","article-title":"Evaluation of Synergistic Activity of Plazomicin-Based Combinations Against KPC-Producing","volume":"34","author":"Iannaccone","year":"2022","journal-title":"J. Chemother."},{"key":"B45","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3390\/antibiotics9090623","article-title":"Overcoming Intrinsic and Acquired Resistance Mechanisms Associated With the Cell Wall of Gram-Negative Bacteria","volume":"9","author":"Impey","year":"2020","journal-title":"Antibiot. (Basel)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e01110","DOI":"10.1128\/AAC.01110-18","article-title":"New Treatment Options Against Carbapenem-Resistant","volume":"63","author":"Isler","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e01454","DOI":"10.1128\/AAC.01454-17","article-title":"Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, Against Gram-Negative Bacteria","volume":"62","author":"Ito","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01801-18","article-title":"ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae\u00a0with Defined Extended-Spectrum \u03b2-Lactamases and Carbapenemases","volume":"63","author":"Jacobs","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1128\/AAC.50.4.1123-1129.2006","article-title":"Beta-Lactamase Nomenclature","volume":"50","author":"Jacoby","year":"2006","journal-title":"Antimicrob. Agents Chemother"},{"key":"B50","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/jac\/dkx393","article-title":"Ceftazidime\/avibactam Alone or in Combination With Aztreonam Against Colistin-Resistant and Carbapenemase-Producing Klebsiella Pneumoniae","volume":"73","author":"Jayol","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14787210.2022.2021876","article-title":"Multicenter Surveillance of In Vitro Activities of Cefepime-Zidebactam, Cefepime-Enmetazobactam, Omadacycline, Eravacycline, and Comparator Antibiotics Against Enterobacterales, Pseudomonas Aeruginosa, and Acinetobacter Baumannii Complex Causing Bloodstream Infection in Taiwan 2020","volume":"11","author":"Jean","year":"2022","journal-title":"Expert. Rev. Anti Infect. Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-To-Treat Resistance in Gram-Negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-Line Agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1089\/mdr.2014.0234","article-title":"Molecular Epidemiology and Mechanisms of Carbapenem Resistance of Acinetobacter Spp. In Asia and Oceania","volume":"21","author":"Kamolvit","year":"2015","journal-title":"Microb. Drug Resist."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e00472","DOI":"10.1128\/AAC.00472-17","article-title":"Activity of Aztreonam-Avibactam Against Enterobacteriaceae and Pseudomonas Aeruginosa Isolated by Clinical Laboratories in 40 Countries From 2012 to 2015","volume":"61","author":"Karlowsky","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00592-18","article-title":"Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program From 2012 to 2015","volume":"62","author":"Kazmierczak","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B56","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","article-title":"In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against a Recent Collection of Clinically Relevant Carbapenem-non-Susceptible Gram-Negative Bacilli, Including Serine Carbapenemase- and Metallo-\u03b2-Lactamase-Producing Isolates (SIDERO-WT-2014 Study)","volume":"53","author":"Kazmierczak","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e02338","DOI":"10.1128\/AAC.02338-20","article-title":"Activity of Cefepime in Combination With the Novel \u03b2-Lactamase Inhibitor Taniborbactam (VNRX-5133) Against Extended-Spectrum-\u03b2-Lactamase-Producing Isolates in In Vitro Checkerboard Assays","volume":"65","author":"Kloezen","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2020.07.009","article-title":"Reduced Susceptibility Mechanism to Cefiderocol, a Siderophore Cephalosporin, Among Clinical Isolates From a Global Surveillance Programme (SIDERO-WT-2014)","volume":"22","author":"Kohira","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B59","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3390\/jcm8060866","article-title":"The Efficacy and Safety of Eravacycline in the Treatment of Complicated Intra-Abdominal Infections: A Systemic Review and Meta-Analysis of Randomized Controlled Trials","volume":"8","author":"Lan","year":"2019","journal-title":"J. Clin. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e506","DOI":"10.1093\/cid\/ciaa1228","article-title":"Attributable Length of Stay, Mortality Risk, and Costs of Bacterial Health Care-Associated Infections in Australia: A Retrospective Case-Cohort Study","volume":"72","author":"Lee","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1021\/ar300327a","article-title":"Class D \u03b2-Lactamases: A Reappraisal After Five Decades","volume":"46","author":"Leonard","year":"2013","journal-title":"Acc. Chem. Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/jac\/dkx438","article-title":"Activity of Ceftazidime\/Avibactam Against Problem Enterobacteriaceae and Pseudomonas Aeruginosa in the UK 2015\u201316","volume":"73","author":"Livermore","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt178","article-title":"Activity of MK-7655 Combined With Imipenem Against Enterobacteriaceae and Pseudomonas Aeruginosa","volume":"68","author":"Livermore","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"B64","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1093\/infdis\/jiw282","article-title":"The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace","volume":"215","author":"Logan","year":"2017","journal-title":"J. Infect. Dis."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01443-17","article-title":"Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae","volume":"61","author":"Lomovskaya","year":"2017","journal-title":"Antimicrob. Agents. Chemother."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e00210","DOI":"10.1128\/AAC.00210-21","article-title":"In Vitro Activity of the Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination With Multiple Beta-Lactam Antibiotics Against Pseudomonas Aeruginosa","volume":"65","author":"Lomovskaya","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B67","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1089\/mdr.2021.0231","article-title":"Increment Antimicrobial Resistance During the COVID-19 Pandemic: Results From the Invifar Network","volume":"28","author":"L\u00f3pez-J\u00e1come","year":"2021","journal-title":"Microb. Drug Resist."},{"key":"B68","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jhin.2017.02.024","article-title":"Dissemination and Clinical Implications of Multidrug-Resistant Klebsiella Pneumoniae Isolates Producing OXA-48 in a Spanish Hospital","volume":"96","author":"Madue\u00f1o","year":"2017","journal-title":"J.\u00a0Hosp. Infect."},{"key":"B69","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-Resistant, Extensively Drug-Resistant and Pandrug-Resistant Bacteria: An International Expert Proposal for Interim Standard Definitions for Acquired Resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e02243","DOI":"10.1128\/AAC.02243-16","article-title":"Can Ceftazidime-Avibactam and Aztreonam Overcome \u03b2-Lactam Resistance Conferred by Metallo-\u03b2-Lactamases in Enterobacteriaceae","volume":"61","author":"Marshall","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1590\/S1517-83822012000400006","article-title":"Imipenem-Resistant Acinetobacter Baumannii Carrying the ISAba1-Bla OXA-23,51 and ISAba1-Bla ADC-7 Genes in Monteria, Colombia","volume":"43","author":"Mart\u00ednez","year":"2012","journal-title":"Braz. J. Microbiol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1093\/jac\/dkab494","article-title":"Clinical and Microbiological Outcomes, by Causative Pathogen, in the ASPECT-NP Randomized, Controlled, Phase 3 Trial Comparing Ceftolozane\/Tazobactam and Meropenem for Treatment of Hospital-Acquired\/Ventilator-Associated Bacterial Pneumonia","volume":"77","author":"Martin-Loeches","year":"2022","journal-title":"J. Antimicrob. Chemother"},{"key":"B73","doi-asserted-by":"publisher","first-page":"e00700","DOI":"10.1128\/AAC.00700-17","article-title":"Efficacy of Cefiderocol Against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics","volume":"61","author":"Matsumoto","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3390\/antibiotics10081012","article-title":"The Revival of Aztreonam in Combination With Avibactam Against Metallo-Beta-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Sudies and Clinical Cases","volume":"10","author":"Mauri","year":"2021","journal-title":"Antibiotics"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e0217120","DOI":"10.1128\/AAC.02171-20","article-title":"New Perspectives on Antimicrobial Agents: Cefiderocol","volume":"65","author":"McCreary","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B76","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1056\/NEJMc1807634","article-title":"Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae","volume":"380","author":"McKinnell","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1089\/mdr.2019.0198","article-title":"Evaluation of Antimicrobial Effects of a New Polymyxin Molecule (SPR741) When Tested in Combination With a Series of \u03b2-Lactam Agents Against a Challenge Set of Gram-Negative Pathogens","volume":"26","author":"Mendes","year":"2020","journal-title":"Microb. Drug Resist."},{"key":"B78","doi-asserted-by":"publisher","first-page":"e00779","DOI":"10.1128\/AAC.00779-19","article-title":"Evaluation of the Synergy of Ceftazidime-Avibactam in Combination With Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin Against Well-Characterized Multidrug-Resistant Klebsiella Pneumoniae and Pseudomonas Aeruginosa","volume":"63","author":"Mikhail","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1021\/acsinfecdis.0c00020","article-title":"Characterization of ETX1317, a Broad-Spectrum \u03b2-Lactamase Inhibitor That Restores and Enhances \u03b2-Lactam Activity Against Multi-Drug-Resistant","volume":"6","author":"Miller","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"B80","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1469-0691.2009.03116.x","article-title":"Acquired Carbapenemases in Gram-Negative Bacterial Pathogens: Detection and Surveillance Issues","volume":"16","author":"Miriagou","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"B81","doi-asserted-by":"publisher","first-page":"e01022","DOI":"10.1128\/AAC.01022-17","article-title":"Efficacy of Humanized Exposures of Cefiderocol (S-649266) Against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model","volume":"61","author":"Monogue","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: A Multicenter, Randomized, Double-Blind Trial Comparing Efficacy and Safety of Imipenem\/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B83","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1093\/cid\/civ523","article-title":"Evolving Resistance Among Gram-Positive Pathogens","author":"Munita","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/jac\/dkab067","article-title":"Activity of Cefepime\/Zidebactam (WCK 5222) Against 'Problem' Antibiotic-Resistant Gram-Negative Bacteria Sent to a National Reference Laboratory","volume":"76","author":"Mushtaq","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1005666","article-title":"Spread of Hospital-Acquired Infections: A Comparison of Healthcare Networks","volume":"13","author":"Nekkab","year":"2017","journal-title":"PloS Comput. Biol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"e00757","DOI":"10.1128\/AAC.00757-20","article-title":"Activity of the Ultrabroad-Spectrum-Beta-Lactamase Inhibitor QPX7728 Against Carbapenem-Resistant","volume":"64","author":"Nelson","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B87","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1128\/AAC.00220-16","article-title":"In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas Aeruginosa to Ceftazidime Avibactam (INFORM 2012 to 2014)","volume":"60","author":"Nichols","year":"2016","journal-title":"Antimicrob. Agents Chemother"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3201\/eid1710.110655","article-title":"Global Spread of Carbapenemase-Producing Enterobacteriaceae","volume":"17","author":"Nordmann","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"B89","doi-asserted-by":"publisher","first-page":"e0109021","DOI":"10.1128\/AAC.01090-21","article-title":"Recent Emergence of Aztreonam-Avibactam Resistance in NDM and OXA-48 Carbapenemase-Producing Escherichia Coli in Germany","volume":"65","author":"Nordmann","year":"2021","journal-title":"Antimicrob Agents Chemother."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1021\/acsinfecdis.0c00019","article-title":"Pharmacokinetic\/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the \u03b2-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug Etx0282","volume":"6","author":"O'Donnell","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"B91","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.cmi.2020.10.016","article-title":"Risk Factors for Carbapenem-Resistant Gram-Negative Bacterial Infections: A Systematic Review","volume":"27","author":"Palacios-Baena","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.3390\/antibiotics10121539","article-title":"Investigating the OXA Variants of ESKAPE Pathogens","volume":"10","author":"Pandey","year":"2021","journal-title":"Antibiot. (Basel)"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1093\/jac\/dkz125","article-title":"Reversal of Carbapenemase-Producing Klebsiella Pneumoniae Epidemiology From blaKPC- to blaVIM-Harbouring Isolates in a Greek ICU After Introduction of Ceftazidime\/Avibactam","volume":"74","author":"Papadimitriou-Olivgeris","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B94","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/infdis\/jiz149","article-title":"Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas Aeruginosa","volume":"220","author":"Papp-Wallace","year":"2019","journal-title":"J. Infect. Dis."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab174","article-title":"Cefiderocol Treatment for Carbapenem-Resistant Acinetobacter Baumannii Infection in the ICU During the COVID-19 Pandemic: A Multicentre Cohort Study","volume":"3","author":"Pascale","year":"2021","journal-title":"JAC Antimicrob. Resist."},{"key":"B96","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1128\/CMR.00058-07","article-title":"Acinetobacter Baumannii: Emergence of a Successful Pathogen","volume":"21","author":"Peleg","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.15585\/mmwr.mm6948e1","article-title":"Increase in Hospital-Acquired Carbapenem-Resistant Acinetobacter Baumannii Infection and Colonization in an Acute Care Hospital During a Surge in COVID-19 Admissions - New Jersey, February-July 2020","volume":"69","author":"Perez","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"B98","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.cmi.2019.03.014","article-title":"Carbapenem-Resistant Acinetobacter Baumannii: In Pursuit of an Effective Treatment","volume":"25","author":"Piperaki","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"B99","doi-asserted-by":"publisher","first-page":"e00102","DOI":"10.1128\/CMR.00102-19","article-title":"The Global Ascendency of OXA-48-Type Carbapenemases","volume":"33","author":"Pitout","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"B100","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/Tazobactam vs Polymyxin or Aminoglycoside-Based Regimens for the Treatment of Drug-Resistant Pseudomonas Aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B101","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1128\/AAC.01512-08","article-title":"Diversity, Epidemiology, and Genetics of Class D Beta-Lactamases","volume":"54","author":"Poirel","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B102","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1089\/mdr.2017.0078","article-title":"Prevalence and Molecular Characterization of New Delhi Metallo-Beta-Lactamases in Multidrug-Resistant Pseudomonas Aeruginosa and Acinetobacter Baumannii From India","volume":"24","author":"Rahman","year":"2018","journal-title":"Microb. Drug Resist."},{"key":"B103","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ijantimicag.2014.03.003","article-title":"Prevalence and Molecular Characterisation of New Delhi Metallo-\u03b2-Lactamases NDM-1, NDM-5, NDM-6 and NDM-7 in Multidrug-Resistant Enterobacteriaceae From India","volume":"44","author":"Rahman","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2021.115343","article-title":"In Vitro Synergy of Ticarcillin\/Clavulanate in Combination With Aztreonam and Ceftolozane\/Tazobactam Against SPM-1-Producing Pseudomonas Aeruginosa Strains","volume":"100","author":"Rocha-Santos","year":"2021","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B105","doi-asserted-by":"publisher","first-page":"e01267","DOI":"10.1128\/AAC.01267-20","article-title":"Activity of QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor, in Combination With Beta-Lactams Against Carbapenem-Resistant Klebsiella Pneumoniae. Antimicrob","volume":"64","author":"Sabet","year":"2020","journal-title":"Agents Chemother."},{"key":"B106","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2018.04.012","article-title":"Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas Aeruginosa Isolates From United States Medical Centers Stratified by Infection Type: Results From the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program 2015-2016","volume":"92","author":"Sader","year":"2018","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B107","doi-asserted-by":"publisher","first-page":"e00311","DOI":"10.1128\/AAC.00311-18","article-title":"Antimicrobial Activity of Murepavadin Tested Against Clinical Isolates of Pseudomonas Aeruginosa From the United States, Europe, and China","volume":"62","author":"Sader","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1093\/jac\/dky227","article-title":"Murepavadin Activity Tested Against Contemporary, (2016-17) Clinical Isolates of XDR Pseudomonas Aeruginosa","volume":"73","author":"Sader","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1093\/jac\/dkx050","article-title":"WCK 5222 (Cefepime\/Zidebactam) Antimicrobial Activity Tested Against Gram-Negative Organisms Producing Clinically Relevant \u03b2-Lactamases","volume":"72","author":"Sader","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B110","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijantimicag.2017.06.022","article-title":"In-Vitro Activity of the Novel Fluorocycline Eravacycline Against Carbapenem Non-Susceptible Acinetobacter Baumannii","volume":"51","author":"Seifert","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz123","article-title":"Plazomicin Is Active Against Metallo-\u03b2-Lactamase-Producing Enterobacteriaceae","volume":"6","author":"Serio","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.709974","article-title":"Durlobactam, a New Diazabicyclooctane \u03b2-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam","volume":"12","author":"Shapiro","year":"2021","journal-title":"Front. Microbiol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4103\/0976-9668.127280","article-title":"Study of Extended Spectru, Beta-Lactamase Producing Enterobacteriaceae and Antibiotic Coresistance in a Tertiary Care Teaching Hospital","volume":"5","author":"Shashwati","year":"2014","journal-title":"J. Nat. Sci. Biol. Med"},{"key":"B114","doi-asserted-by":"publisher","first-page":"e00883","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-Avibactam Is Superior to Other Treatment Regimens Against Carbapenem-Resistant Klebsiella Pneumoniae Bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B115","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","article-title":"Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"B116","doi-asserted-by":"publisher","first-page":"64","DOI":"10.18231\/2394-5478.2017.0013","article-title":"Detection of Co-Existence of Beta-Lactamases in Gram Negative Bacteria Using Disc Potentiation Tests","volume":"4","author":"Shivana","year":"2017","journal-title":"Indian J. Microbiol. Res"},{"key":"B117","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1089\/mdr.2017.0266","article-title":"Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas Aeruginosa With Various Resistance Patterns Isolated in U.S. Hospitals, (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility","volume":"24","author":"Shortridge","year":"2018","journal-title":"Microb. Drug Resist."},{"key":"B118","doi-asserted-by":"publisher","first-page":"ofab311","DOI":"10.1093\/ofid\/ofab311","article-title":"Cefiderocol Activity Against Clinical Pseudomonas Aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance","volume":"8","author":"Simner","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"B119","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1093\/jac\/dkx139","article-title":"Prospective, Randomized, Double-Blind, Phase 2 Dose-Ranging Study Comparing Efficacy and Safety of Imipenem\/Cilastatin Plus Relebactam With Imipenem\/Cilastatin Alone in Patients With Complicated Urinary Tract Infections","volume":"72","author":"Sims","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B120","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1073\/pnas.0400456101","article-title":"Persistent Colonization and the Spread of Antibiotic Resistance in Nosocomial Pathogens: Resistance is a Regional Problem","volume":"101","author":"Smith","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02253-13","article-title":"Persistent Colonization and the Spread of Antibiotic Resistance in Nosocomial Pathogens: Resistance is a Regional Problem Isolates","volume":"58","author":"Snydman","year":"2014","journal-title":"Antimicrob. Agents. Chemother."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s40121-021-00507-6","article-title":"Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections With Limited Treatment Options: A Systematic Literature Review","volume":"10","author":"Soriano","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"B123","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/nrd3957-c1","article-title":"The Value of Single-Pathogen Antibacterial Agents","volume":"12","author":"Spellberg","year":"2013","journal-title":"Nat. Rev. Drug Discovery"},{"key":"B124","doi-asserted-by":"publisher","first-page":"e00239","DOI":"10.1128\/AAC.00239-18","article-title":"Assessment of the\u00a0In Vivo\u00a0Activity of SPR741 in Combination with Azithromycin against Multidrug-Resistant Enterobacteriaceae Isolates in the Neutropenic Murine Thigh Infection Model","volume":"62","author":"Stainton","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B125","doi-asserted-by":"publisher","first-page":"e01040","DOI":"10.1128\/AAC.01040-18","article-title":"Efficacy of Humanized Cefiderocol Exposures Over 72 Hours Against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model","volume":"63","author":"Stainton","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B126","doi-asserted-by":"publisher","first-page":"e01195","DOI":"10.1128\/AAC.01195-18","article-title":"Treatment of Infections by OXA-48-Producing Enterobacteriaceae","volume":"62","author":"Stewart","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B127","doi-asserted-by":"publisher","first-page":"ciab1013","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America Guidance on the Treatment of AmpC \u03b2-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter Baumannii, and Stenotrophomonas Maltophilia Infections","author":"Tamma","year":"2021","journal-title":"Clin. Infect. Dis"},{"key":"B128","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","article-title":"Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum \u03b2-Lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas Aeruginosa With Difficult-To-Treat Resistance (DTR-P. Aeruginosa)","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1093\/cid\/ciz173","article-title":"A Primer on AmpC \u03b2-Lactamases: Necessary Knowledge for an Increasingly Multidrug-Resistant World","volume":"69","author":"Tamma","year":"2019","journal-title":"Clin. Infect. Dis"},{"key":"B130","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/cid\/ciw741","article-title":"Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.137\/jurnal.pone.0241984","article-title":"Extended-Spectrum Beta-Lactamase and AmpC Beta-Lactamases Producing Gram Negative Bacilli Isolated From Clinical Specimens at International Clinical Laboratories, Addis Ababa, Ethipia","volume":"15","author":"Tekele","year":"2020","journal-title":"PloS One"},{"key":"B132","doi-asserted-by":"publisher","first-page":"323","DOI":"10.7883\/yoken.66.323","article-title":"Outbreak of Multiresistant OXA-24- and OXA-51-Producing Acinetobacter Baumannii in an Internal Medicine Ward","volume":"66","author":"Tena","year":"2013","journal-title":"Jpn. J. Infect. Dis."},{"key":"B133","doi-asserted-by":"publisher","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A Randomized, Double-Blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem\/Cilastatin\/Relebactam Versus Piperacillin\/Tazobactam in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (RESTORE-IMI 2 Study)","volume":"73","author":"Titov","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B134","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella Pneumoniae Carbapenemase-Producing K. Pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B135","article-title":"Ceftazidime\/Avibactam Q20 (Avycaz\u00ae), National Drug Monograph","volume-title":"Pharmacy Benefits Management Services","year":"2015"},{"key":"B136","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3390\/molecules24020249","article-title":"Polymyxin Derivatives That Sensitize Gram-Negative Bacteria to Other Antibiotics","volume":"24","author":"Vaara","year":"2019","journal-title":"Molecules"},{"key":"B137","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"B138","doi-asserted-by":"publisher","first-page":"e01730","DOI":"10.1128\/AAC.01730-17","article-title":"A Systematic Review and Meta-Analyses of the Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae","volume":"62","author":"van Loon","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3201\/eid2507.181200","article-title":"Carbapenem-Resistant Pseudomonas Aeruginosa at US Emerging Infections Program Site","volume":"25","author":"Walters","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"B140","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jgar.2019.12.009","article-title":"Resistance to Ceftazidime-Avibactam and Underlying Mechanisms","volume":"22","author":"Wang","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B141","doi-asserted-by":"publisher","first-page":"e0195281","DOI":"10.1371\/journal.pone.0195281","article-title":"Prevalence of Mcr-Type Genes Among Colistin-Resistant Enterobacteriaceae Collected in 2014-2016 as Part of the INFORM Global Surveillance Program","volume":"13","author":"Wise","year":"2018","journal-title":"PLoS One"},{"key":"B142","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1128\/CMR.00058-16","article-title":"Clinical and Pathophysiological Overview of Acinetobacter Infections: A Century of Challenges","volume":"30","author":"Wong","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"B143","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and Safety of Meropenem-Vaborbactam Versus Best-Available Therapy in Patients With Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"B144","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol Versus High-Dose, Extended-Infusion Meropenem for the Treatment of Gram-Negative Nosocomial Pneumonia (APEKS-NP): A Randomised, Double-Blind, Phase 3, Non-Inferiority Trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B145","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41426-018-0038-9","article-title":"Analysis of Global Prevalence of Antibiotic Resistance in Acinetobacter Baumannii Infections Disclosed a Faster Increase in OECD Countries","volume":"7","author":"Xie","year":"2018","journal-title":"Emerg. Microbes Infect."},{"key":"B146","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1093\/jac\/dkaa217","article-title":"Evaluation of the In Vitro Activity of New Polymyxin B Analogue SPR206 Against Clinical MDR, Colistin-Resistant and Tigecycline-Resistant Gram-Negative Bacilli","volume":"75","author":"Zhang","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"B147","doi-asserted-by":"publisher","first-page":"e01239","DOI":"10.1128\/AAC.01239-17","article-title":"SPR741, an Antibiotic Adjuvant, Potentiates the\u00a0In Vitro\u00a0and\u00a0In Vivo\u00a0Activity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii","volume":"61","author":"Zurawski","year":"2017","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.884365\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T10:07:52Z","timestamp":1662545272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.884365\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,20]]},"references-count":147,"alternative-id":["10.3389\/fcimb.2022.884365"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.884365","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,20]]},"article-number":"884365"}}